Lilly to boost Indianapolis manufacturing site with $400m injection, 100 jobs to be created
pharmafile | November 20, 2019 | News story | Manufacturing and Production, Research and Development | Eli Lilly, US, pharma
Eli Lilly is poised to boost its manufacturing capacity with the investment of $400 million at its Lilly Technology Center campus in Indianapolis, the company announced, in a move to step up to increasing demand for its medicines.
According to the company, this investment will create around 100 new “highly skilled” positions at the site, as well as deliver enhancements to its insulin-producing manufacturing facilities, expand its capability to further develop its diabetes portfolio, and provide initial capital investments for products it aims to develop in the future.
The investment is the latest in $5 billion that Lilly has committed to its US operations since 2012. Of this figure, its Indiana facilities have been the primary beneficiary, while just under $2 billion of the sum has gone directly into the manufacture of its diabetes medications.
“These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the United States, and have been made possible by the tax reform measures passed by Congress in 2017,” commented David A Ricks, Lilly’s Chairman and Chief Executive Officer. “With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home. This is crucial for us to continue to advance our state’s economy and drive future investment – adding high-tech jobs and facilities that keep Indiana competitive in the global marketplace.”
Myles O’Neill, Senior Vice President and President of Manufacturing Operations at the company, echoed these sentiments, remarking: “These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations. All of these projects support Lilly’s investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics.”
Matt Fellows
Related Content
Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity
Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated …
Amgen opens new biomanufacturing facility in Ohio, US
Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. …
Zuellig Pharma acquires Cialis and Alimta from Eli Lilly in certain ASEAN markets
Zuellig Pharma has announced that it has completed the acquisition of two brands Cialis (Tadalafil) …
